Trace analysis of rapamycin in human blood by micellar electrokinetic chromatography

Buchberger, Wolfgang; Ferdig, Matthias; Sommer, Rudolf; Thuy Diep; Thanh Vo
September 2004
Analytical & Bioanalytical Chemistry;Sep2004, Vol. 380 Issue 1, p68
Academic Journal
A capillary electrophoretic method with UV detection at 278 nm has been developed for analysis of the immunosuppressant rapamycin (sirolimus) in human blood at low microgram per liter levels. Separation has been achieved in an acidic carrier electrolyte containing sodium dodecylsulfate and 30% (v/v) acetonitrile. For sample clean-up and preconcentration, an off-line solid-phase extraction step using a silica-based reversed-phase material and an on-capillary focussing technique were employed. The latter allows the injection of increased sample volumes without excessive band broadening. Although this new method is less sensitive than existing liquid chromatographic procedures combined with mass spectrometry, it is fully suited to routine analysis of rapamycin in blood from patients treated with this drug. Last but not least the low costs make it an attractive alternative to established methods.


Related Articles

  • Reliability of Everolimus Determination in the Viva Vitalab Analyser. Codejon, Olga Fernandez; Gasos, Maria Palacios; Letosa, Roberto Marcen; Rodriguez, Ana Fernandez; Sevillano, Eduardo Ripoll; Villafruela Sanz, Juan Jose // Journal of US-China Medical Science;Jul2011, Vol. 8 Issue 7, p385 

    Everolimus is a potent immunosuppressive agent with anticarcinogenetic properties that is used in many kinds of solid organ transplantation and in different oncologic therapies. Until the recent incorporation of the QMS� (Quantitative Microparticle System) turbidimetric method, the only...

  • mTOR regulates pyrimidine synthesis. Trajkovska, Maria // Nature Cell Biology;Apr2013, Vol. 15 Issue 4, p351 

    The article discusses two studies published in "Science" journal which revealed the role of the mammalian target of rapamycin (mTOR) in regulating the pyrimidine synthesis pathway.

  • SAKURA Study 1: Intravitreal sirolimus safe for noninfectious uveitis of posterior segment. Hasson, Matt // Ocular Surgery News;4/25/2015, Vol. 33 Issue 8, p38 

    The article discusses a study which found the safety and effectiveness of intravitreal sirolimus and is a viable alternative to cortico-steroids in the long-term treatment of chronic noninfectious uveitis of the posterior segment. Topics covered include the role of the injection in the reduction...

  • Autophagy Induction by Endothelial-Monocyte Activating Polypeptide II Contributes to the Inhibition of Malignant Biological Behaviors by the Combination of EMAP II with Rapamycin in Human Glioblastoma. Jun Ma; Fanjie Meng; Shuai Li; Libo Liu; Lini Zhao; Yunhui Liu; Yi Hu; Zhen Li; Yilong Yao; Zhuo Xi; Hao Teng; Yixue Xue; Braun, Ralf J.; Zhongya Wang // Frontiers in Molecular Neuroscience;Dec2015, p1 

    This study aims to investigate the effect of endothelial-monocyte activating polypeptide II (EMAP II) on human glioblastoma (GBM) cells and glioblastoma stem cells (GSCs) as well as its possible mechanisms. In this study, EMAP II inhibited the cell viability and decreased the mitochondrial...

  • Nature: Charting autism's neural circuitry.  // Biomedical Market Newsletter;7/19/2012, Vol. 21, p1 

    The article discusses the immunosuppressant drug called rapamycin that can prevent autistic-like symptoms caused by the deletion of a single gene from the cerebellum.

  • Renal cortical necrosis in a renal transplant recipient. Eswarappa, M.; Ravi, V.; Mysorekar, V. // Indian Journal of Nephrology;May/Jun2013, Vol. 23 Issue 3, p238 

    The article discusses a case study of a 49-year-old male with chronic kidney disease who received a renal transplant. The patient was administered everolimus, mycophenolate mofetil and steroids, and developed intermittent fever and breathlessness 4 years after the transplant. The article...

  • All Roads, as We Know, Lead to MTOR. Breindl, Anette // BioWorld Today;8/5/2013, Vol. 24 Issue 148, Special section p2 

    The article discusses research which implicated mammalian target of rapamycin (mTOR) signaling in the resistance of tumor cells to separate classes of therapeutics, which appeared in the August 1, 2013 issue of "Science Translational Medicine."

  • Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Guba, Markus; von Breitenbuch, Philipp; Steinbauer, Markus; Koehl, Gudrun; Flegel, Stefanie; Hornung, Matthias; Bruns, Christiane J.; Zuelke, Carl; Farkas, Stefan; Anthuber, Matthias; Jauch, Karl-Walter; Geissler, Edward K. // Nature Medicine;Feb2002, Vol. 8 Issue 2, p128 

    Conventional immunosuppressive drugs have been used effectively to prevent immunologic rejection in organ transplantation. Individuals taking these drugs are at risk, however, for the development and recurrence of cancer. In the present study we show that the new immunosuppressive drug rapamycin...

  • Drug Linked With Diabetes. Hampton, Tracy // JAMA: Journal of the American Medical Association;6/6/2012, Vol. 307 Issue 21, p2247 

    The article informs that the diabetes-like symptoms and insulin resistance are caused by immunosuppressant drug rapamycin that are used for cancer therapies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics